Fighting Alzheimer's disease with protein origami

Figure 1: Prefoldin protein expression (green) in mice with high levels of amyloid-β in their brains (cell nuclei stained in blue). Credit: 2013 American Chemical Society

Alzheimer's disease is a progressive degenerative brain disease most commonly characterized by memory deficits. Loss of memory function, in particular, is known to be caused by neuronal damage arising from the misfolding of protein fragments in the brain. Now, a group of researchers led by Mizuo Maeda of the RIKEN Bioengineering Laboratory, and including researchers from the Laboratory for Proteolytic Neuroscience at the RIKEN Brain Science Institute, has found that the human protein prefoldin can change the way these misfolded protein aggregates form and potentially reduce their toxic impact on the brains of Alzheimer's patients.

The formation of insoluble fibril aggregates of the protein amyloid-? has been identified as a key mechanism responsible for memory loss in Alzheimer's patients. These fibrils are toxic to neurons, and finding a means of preventing their formation represents a key strategy in the development of a therapy for the disease. Recent studies suggest methods that alter the mechanism of amyloid-? aggregates could offer a promising approach.

Prefoldin is a involved in preventing the clumping of misfolded proteins and helping misfolded proteins return to their normal shape. The researchers found that amyloid-? molecules incubated with even just a small amount of human prefoldin underwent a change in aggregation behavior—they instead formed into small, soluble oligomer clumps. The observations suggest that human prefoldin interacts with amyloid-? molecules to alter their binding properties.

As in the brain, amyloid-? fibrils also kill neurons in cell culture. Using neurons from the brains of mice, the researchers showed that the amyloid-? oligomers formed in the presence of human prefoldin induced less than amyloid-? fibrils. Prefoldin expression actually increases in the brains of mice with high levels of amyloid-? (Fig. 1), suggesting that the upregulation of prefoldin expression might be a response mechanism used by the brain to protect itself from the toxic effects of amyloid-? fibrils.

Many researchers currently believe that amyloid-? oligomers are themselves a toxin that induces neuronal dysfunction. The present results, however, suggest that certain types of oligomers may in fact be less toxic than other conformations of amyloid-? aggregates. Increasing the expression of human prefoldin in the brain may therefore increase the proportion of less toxic amyloid-? aggregates, presenting a potential means of fighting the disease.

"Our findings may also apply to various other neurological diseases caused by protein misfolding, such as prion disease, Huntington's disease and Parkinson's disease," explains Tamotsu Zako from the research team.

More information: Sörgjerd, K. et al. Human prefoldin inhibits amyloid-? (A?) fibrillation and contributes to formation of non-toxic A? aggregates. Biochemistry 52, 3532–3542 (2013). dx.doi.org/10.1021/bi301705c

Related Stories

Researchers investigate mechanism of Alzheimer's therapy

date Jul 08, 2013

Researchers at the University of Kentucky Sanders-Brown Center on Aging, led by faculty member Donna Wilcock, have recently published a new paper in the Journal of Neuroscience detailing an advance in tre ...

A molecular chain reaction in Alzheimer's disease

date May 29, 2013

Researchers at Lund University in Sweden have identified the molecular mechanism behind the transformation of one of the components in Alzheimer's disease. They identified the crucial step leading to formations that kill ...

Recommended for you

Volunteers in Tunisia develop app for Alzheimer's patients

date 4 hours ago

About a year ago, Azer Jaafoura and a few of his colleagues at Samsung Electronics Tunisia (SETN) were thinking of helping out Alzheimer's patients. However, with a full-time job and already volunteering at a children's hospital, ...

Helpful app for people with dementia

date Apr 21, 2015

Bangor University is providing expertise to support the development and effectiveness of 'Book of You', an 'app' being welcomed as having the potential to revolutionise reminiscence therapy for people with dementia.

New approaches for early diagnosis of Alzheimer's

date Apr 17, 2015

Mild cognitive impairment, or MCI, may be one of Alzheimer's earliest signs. The subtle changes of MCI include problems with memory, language, thinking and judgment and a subjective sense that mental function ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.